These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15735792)

  • 1. Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
    Peternel L; Stegnar M; Drevensek G; Budihna MV; Bozic M; Zega A; Stalc A; Cerne M; Urleb U
    Thromb Haemost; 2005 Mar; 93(3):437-42. PubMed ID: 15735792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
    Cho JH; Yun CH; Seo HS; Koga T; Dan T; Koo BA; Kim HY
    Thromb Haemost; 2001 Dec; 86(6):1512-20. PubMed ID: 11776321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
    Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D
    Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct thrombin inhibitors built on the azaphenylalanine scaffold provoke degranulation of mast cells.
    Peternel L; Stempelj M; Cerne M; Zega A; Obreza A; Oblak M; Drevensek G; Budihna MV; Stanovnik L; Urleb U
    Thromb Haemost; 2006 Feb; 95(2):294-300. PubMed ID: 16493492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN; Girard D; Lochot S; Lecoffre C
    Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
    Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
    Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
    Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
    Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
    Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
    Br J Pharmacol; 1998 Jan; 123(1):92-6. PubMed ID: 9484858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histamine release, an undesired effect of thrombin inhibitors with basic character, is mediated through direct activation of G(i) proteins.
    Stempelj M; Zorko M; Peternel L; Urleb U; Ferjan I
    Eur J Pharmacol; 2006 May; 538(1-3):182-7. PubMed ID: 16650405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
    Elg M; Gustafsson D; Deinum J
    Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
    Hiebert LM
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
    Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
    J Thromb Haemost; 2007 Jun; 5(6):1237-42. PubMed ID: 17362226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
    Farias WR; Nazareth RA; Mourão PA
    Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.
    Leblond L; Grouix B; Boudreau C; Yang Q; Siddiqui MA; Winocour PD
    Thromb Res; 2000 Nov; 100(3):195-209. PubMed ID: 11108907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.